This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): QAB149, Onbrez/Hirobriz/Oslif Breezhaler (EU), indacaterol maleate
Description: QAB149 is a long acting beta-2 agonist. It is a bronchodilator that has a rapid-onset of action with a 24 hour duration of action.
The first generation delivery device for QAB149 is the CONCEPT1 inhaler.
Deal Structure: In December 2003, SkyePharma announced an agreement with Novartis to jointly develop a new product for the treatment of asthma and COPD. The product combines QAB 149, Novartis' novel long-acting bronchodilator, with two SkyePharma technologies: the SkyeHaler, a breath-activated multi-dose dry powder inhaler (MDDPI) device, to be marketed by Novartis as the Certihaler and SkyeProtect, a powder formulation that protects the drug from atmospheric moisture to ensure product stability and dose-to-dose reproducibility. SkyePharma is performing technical development and supplying clinical trial material, while Novartis is responsible for the other aspects of the development process. Novartis made an initial payment on signature of the agreement and will make future payments on attainment of development milestones and will pay SkyePharma royalties on eventual sales.
In September 2006, QAB 149 advanced with the CONCEPT1 inhaler. As a result, we believe the partnership with SkyePharma has...See full deal structure in Biomedtracker
Arcapta Neohaler News
Additional information available to subscribers only: